<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01845350</url>
  </required_header>
  <id_info>
    <org_study_id>STR-M2-2013</org_study_id>
    <nct_id>NCT01845350</nct_id>
  </id_info>
  <brief_title>Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients</brief_title>
  <official_title>Safety and Feasibility of Autologous M2 Macrophage Transplantation in Treatment of Non-Acute Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Siberian Branch of the Russian Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Siberian Branch of the Russian Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether M2 macrophages are safe and feasible in the
      treatment of non-acute stroke patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our primary hypothesis is that autologous M2 macrophage transplantation via intrathecal
      introduction is feasible and safe after non-acute stroke. Our secondary hypothesis is that
      autologous M2 macrophage transplantation is associated with improved neurological outcome
      after non-acute stroke
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients with severe adverse events</measure>
    <time_frame>1-3 days, 6 months</time_frame>
    <description>Occurence of severe adverse events including mortality, neurological worsening and seizures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of functional outcome in National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>1-3 days, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Barthel Index</measure>
    <time_frame>1-3 days, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in modified Rankin scale</measure>
    <time_frame>1-3 days, 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with recurrent vascular episodes</measure>
    <time_frame>1-3 days, 6 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Hemorrhagic Stroke</condition>
  <arm_group>
    <arm_group_label>M2 macrophages</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>M2 macrophage introduction</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>M2 macrophage introduction</intervention_name>
    <description>Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients
Intrathecal introduction of autologous M2 macrophages</description>
    <arm_group_label>M2 macrophages</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Computed tomography confirmed ischemic or hemorrhagic stroke

          -  Duration since stroke onset more than 3 and less than 12 months

          -  Age between 18 and 75 years old

          -  Persistent neurological deficits more than 4 points in NIHSS stroke scale

          -  Signed informed consent

        Exclusion Criteria:

          -  The history of previous stroke

          -  Seizures

          -  Thrombophilias or primary hematological diseases

          -  Malignancy

          -  Hepatic or renal dysfunctions

          -  Hemodynamic or respiratory instability

          -  Autoimmune disease

          -  HIV or uncontrolled bacterial, fungal, or viral infections

          -  Pregnancy

          -  Participation in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena R. Chernykh, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Research Institute of Clinical Immunology, Russian Academy of Medical Sciences (Siberian Branch)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Clinical Immunology, Russian Academy of Medical Sciences (Siberian Branch)</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <results_reference>
    <citation>Chernykh ER, Shevela EY, Starostina NM, Morozov SA, Davydova MN, Menyaeva EV, Ostanin AA. Safety and Therapeutic Potential of M2 Macrophages in Stroke Treatment. Cell Transplant. 2016;25(8):1461-71. doi: 10.3727/096368915X690279. Epub 2015 Dec 14.</citation>
    <PMID>26671426</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2013</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Siberian Branch of the Russian Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ekaterina Y. Shevela</investigator_full_name>
    <investigator_title>Senior Researcher, Laboratory of Cellular Therapy, Research Institute of Clinical Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

